4 Promising Oncology Stocks to Consider Adding to Your Portfolio
StockNews
Published Jun 11, 2021 04:30PM ET
Updated Jun 11, 2021 05:30PM ET
4 Promising Oncology Stocks to Consider Adding to Your Portfolio
The Biotech industry has been working to develop cancer treatments for a long time. But now, with tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca (NASDAQ:AZN), Amgen (AMGN), Incyte (NASDAQ:INCY), and Champions Oncology (NASDAQ:CSBR) are valuable additions to one’s portfolio now. So, let’s examine these companies more closely.Cancer is one of the most researched diseases globally, with innumerable research companies with extensive drug pipelines developing treatments and therapies for the disease. Nearly 2 million new cancer cases are expected to be diagnosed in the United States this year, and more than 600,000 of those cases are expected to be fatal.
Thus, biotech companies are under pressure to develop effective drugs to combat the disease. They have been conducting multiple clinical trials to extend cancer patients’ survival rates and duration of response and are adopting advanced technologies in immunotherapies to capitalize on the heightened need for cancer treatments. The global interventional oncology market is expected to grow at a 6.8% CAGR over the next five years to hit $2.9 billion by 2026. In fact, positive results from clinical trials reported by multiple biotech companies have boosted investor optimism regarding the growth potential of this industry. This is evident in Loncar Cancer Immunotherapy ETF’s (CNCR) 7.2% returns over the past month versus SPDR S&P 500 Trust ETF’s (SPY) 1.4% gains.
Given this backdrop, we believe AstraZeneca PLC (AZN), Amgen Inc . (NASDAQ:AMGN), Incyte Corporation (INCY), and Champions Oncology, Inc. (CSBR) could be ideal investment bets now.
Continue reading on StockNews
Get The News You Want
Written By: StockNews
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.